The United States Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) inspection at Wanbury’s facility at Tanuku, West Godavari District, Andhra Pradesh during the period from July 13, 2026 to July 17, 2026.
At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The company will respond to these observations to FDA within the stipulated time.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
